Matthew Perry Investigation: Can Ketamine Kill Someone?

Updated Aug 17, 2024 | 12:00 PM IST

SummaryNew evidence has come up in the investigation of Matthew Perry, 'Friends' Chandler Bing's death on October 28. This evidence points to an overdose of ketamine. What is ketamine and how does it affect you? Read now.
Matthew Perry Investigation Can Ketamine Kill Someone

Credits: IMDb

“I'm not great at the advice. Can I interest you in a sarcastic comment?”

Friends Actor Matthew Perry

This is what ‘Friends’ actor Matthew Perry’s character Chandler Bing was known for. He was known for being funny. However, he had his own struggles in his personal life and those struggles were acute depression. He was treating it with ketamine infusion therapy which is legal in the US and the UK.

What is Ketamine infusion therapy?

Ketamine is an anaesthetic used to treat depression, anxiety and pain under supervised and controlled medical settings. However, it does have its side effects, which can lead to distortion of sight, sound and time. It can also produce calming and relaxing effects.

Ketamine increases a person’s heart rate and blood pressure. If overdosed, it can leave users confused and agitated and can cause them to hurt themselves without even realising it. It can also lead to liver damage and bladder problems.

However, when used in moderation and under the supervision of medical doctors, it can treat depression where traditional antidepressants have failed.

Prof Rupert McShane, a University of Oxford psychiatrist who runs an NHS ketamine treatment clinic told BBC that ketamine “probably turns off the area of the brain that is involved in disappointment.”

Can Ketamine Infusion Therapy Kill Someone?

In simple terms, it cannot, be if the dosage is given in a controlled setting and as prescribed. Ketamine infusion therapy uses drugs in small doses than those used for anaesthesia. It acts faster than traditional anti-depressants, but the effects also wear off way quickly. Which is why it is important to monitor patients’ mental state for relapsing back into depression and discouraging them from overdosing on it.

There are ways of giving people ketamine. One of the ways is through “infusing”, which means to use an IV drip. However, injections, nasal sprays and capsules are also methods used to give people ketamine.

Since the dosage of ketamine used in the infusion treatment is small, it being the reason of actor Perry’s death was ruled out. The medical examiner also noted that Perry’s last ketamine infusion therapy session happened more than a week before his death, which means by the time he had died, it must have worn off.

So, What Happened To Perry?

Though Perry’s last session was more than a week before, his post-mortem showed that his blood contained a high concentration of ketamine. He had died of the “acute effects” of ketamine.

If it was not his session, then how did he get ketamine?

Prosecutors alleged that his assistant gave him at least 27 shots of ketamine in four days before his death, reported BBC.

Perry has been open about his personal struggles and this is what the doctors and dealers used against him. Martin Estrada, the US attorney for California’s Central District told the BBC that people took advantage of his condition. They charged him 165 times more than what vials of ketamine cost.

Names that have come up include Dr Salvador Plasencia, drug dealers “Ketamine Queen” aka Jasveen Sangha and Eric Fleming, and Perry’s live-in assistant Kenneth Iwamasa.

Who Are These Names And What Did They Do?

Ketamine Queen or Sangha supplied drugs that led to Perry’s death. Her home was a “drug-selling emporium,” said Estrada. More than 80 vials of ketamine, and thousands of pills including methamphetamine, cocaine and Xanax were allegedly found in her house known as the “Sangha Stash House.”

Sangha is known to deal with high-end celebs and was a “major source of supply for ketamine to others as well as Perry,” said Estrada.

Dr Plasencia called Perry a “moron” while charging him $2,000 for vials that cost only $12. He sold Perry 20 vials of ketamine between September and October 2023, costing $55,000.

He was the one who taught Iwamasa, who had no medical knowledge to inject the drug. This is after he knew that “Perry’s ketamine addiction was spiralling out of control,” as per what the investigators told the BBC.

Another dealer Fleming was told by Sangha to “delete all our messages.” While Fleming pleaded guilty to conspiring to distribute drugs unlawfully, he also allegedly messaged Sangha: “Please call...Got more info and want to bounce ideas off you. I’m 90% sure everyone is protected. I never dealt with [Perry] only his assistant. So the assistant was the enabler.”

The court documents also revealed that he asked Sangha on whether the ketamine stays in your system or “is it immediately flushed out.”

Dr Pepper, Bots, Cans

The people who allegedly exploited Perry used coded language for ketamine and called it “Dr Pepper”, “bots”, or “cans.”

Selling overpriced drugs, taking advantage of Perry’s mental condition and falsifying medical records to make the drugs given to him look legitimate by Dr Plasencia is what took Perry’s life.

Iwamasa is said to have administered more than 20 shots of ketamine and three on the day Perry died. Whereas ketamine is only administered by a physician. Authorities also found that weeks before Perry’s death, Dr Plasencia allegedly bought 10 vials of ketamine and intended to sell to Perry.

He also injected Perry with a large dose, two days later. This caused him to “freeze up” and spiked his blood pressure.

When I Die, I Want Helping Others To Be The First Thing That’s Mentioned

Perry had always been open about his drug addictions, struggles with alcohol and his depression. He said that his openness would help others who are also struggling and wanted to be remembered by his quote which also is on the homepage of the Mattew Perry Foundation that helps others struggling with the disease of addiction: “When I die, I want helping others to be the first thing that’s mentioned.”

Five arrests have been made in the case so far.

End of Article

India Moves Into The Trajectory Of Developed World, Doubles Social Security Expenditure In A Decade

Updated Nov 17, 2026 | 04:15 PM IST

SummaryThe National Health Accounts (NHA) Estimates for India 2023–24 revealed that government health expenditure more than tripled over the past decade, rising from ₹1,29,778 crore in 2013–14 to ₹4,14,196 crore in 2023–24.
India Moves Into The Trajectory Of Developed World, Doubles Social Security Expenditure In A Decade

Credit: AI Image

India’s social security expenditure on health nearly doubled as a share of Total Health Expenditure, rising from 6% in 2013–14 to 11% in 2023–24, according to the Union Health Ministry. The spending, estimated to have crossed Rs 1 lakh crore, aims to protect individuals and families against the financial risks associated with medical treatment.

This growth has been led by whopping contributions of the government's flagship health insurance schemes such as Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana (AB PM-JAY), state-specific health insurance schemes, social health insurance and medical expenditure for government employees.

Private health insurance expenditure also increased, rising from 3.4% of Total Health Expenditure in 2013-14 to 10.2% in 2023-24.

Government Health Expenditure Triples In A Decade

Also read: Ayushman Bharat Turns 8: PM Modi Highlights Record Savings On Medical Expenses

According to the National Health Accounts (NHA) Estimates for India 2023-24, released by the Ministry of Health and Family Welfare, India’s government health expenditure nearly tripled over the past decade, increasing from Rs 1,29,778 crore in 2013-14 to Rs 4,14,196 crore in 2023-24.

The government’s share of Total Health Expenditure (THE) increased by 14.9 percentage points over the decade, representing a rise of nearly 52%.

The report also highlighted an increase in per-capita government health expenditure and a decline in households’ out-of-pocket spending on healthcare.

“A healthier India. Lower financial burden. Stronger healthcare for all!” Union Health Minister JP Nadda said in a post on X while sharing the data.

"The National Health Accounts 2023–24 tell a powerful story of India’s healthcare transformation over the last decade," he added.

India Moves Into The Trajectory Of Developed World, Doubles Social Security Expenditure In A Decade

Per-Capita Government Health Spending Rises 184% In A Decade

Per-capita government health expenditure increased by 184% over the decade, nearly tripling from Rs 1,042 in 2013-14 to Rs 2,959 in 2023-24.

Spending crossed Rs 2,000 in 2019-20, reaching Rs 2,014, and rose further to Rs 2,328 in 2020-21.

The highest per-capita expenditure was recorded in 2021-22 at Rs 3,169, driven by emergency COVID-19 spending. It subsequently declined by 12.1% to Rs 2,786 in 2022-23 before increasing by 6.2% to Rs 2,959 in 2023-24.

The year-on-year growth rate peaked at 36.1% in 2021-22. Among the years that recorded an increase, the lowest growth was 6.2% in 2023-24.

“These are not just numbers. They reflect a decade of sustained efforts to make quality healthcare more affordable,” Nadda said.

He attributed the progress to initiatives such as Ayushman Bharat and Ayushman Arogya Mandirs under Prime Minister Narendra Modi. He also highlighted expanded access to free medicines and diagnostics as part of efforts to strengthen healthcare delivery.

"Our commitment is simple: No family should have to choose between its health and its financial well-being. A Swasth Bharat is the foundation of a Viksit Bharat!" Nadda said.

Public Investment In Primary Healthcare Triples

Public investment in primary healthcare also nearly tripled over the decade, rising from Rs 50,010 crore in 2013-14 to Rs 1,52,771 crore in 2023-24, according to the NHA estimates.

Out-Of-Pocket Health Expenditure Falls

Read More: India Digitalizes Health Records Of 100 Crore People Under Ayushman Bharat

The share of out-of-pocket expenditure (OOPE) in Total Health Expenditure declined from 64.2% in 2013-14 to 42.7% in 2023-24, a drop of 21.5 percentage points.

This indicates that households are paying a smaller share of overall healthcare costs directly, while other financing sources, including government spending and health insurance, account for a larger share.

Government Initiatives Expanding Access To Affordable Healthcare

The Ministry also highlighted several initiatives aimed at improving access to affordable healthcare across the country. These include:

  • Free Drugs and Diagnostics Initiatives
  • Pradhan Mantri National Dialysis Programme
  • Pradhan Mantri Bhartiya Janaushadhi Pariyojana
  • Affordable Medicines and Reliable Implants for Treatment (AMRIT) pharmacies.

End of Article

'Viagra For The Brain': New Pill Slows Decline in Memory, Thinking By 31% In Some Alzheimer's Patients

Updated Nov 17, 2026 | 11:08 AM IST

SummaryDeveloped by South Korean pharmaceutical company AriBio, the drug, AR1001 (mirodenafil), slowed disease progression including memory, thinking, and everyday functioning by the equivalent of 3.5 months over one year.
'Viagra For The Brain': New Pill Slows Decline in Memory, Thinking By 31% In Some Alzheimer's Patients

Credit: iStock

A new once-daily experimental pill slowed the decline in memory, thinking, and everyday functioning by 31% in some people with Alzheimer's disease in a Phase 3 trial.

Developed by South Korean pharmaceutical company AriBio, the drug, AR1001 (mirodenafil), slowed disease progression by the equivalent of 3.5 months over one year.

Unlike existing dementia drugs, which primarily alleviate symptoms, AR1001 has shown potential to slow disease progression.

However, the benefit was significant only among patients who were not taking other dementia medications.

The company announced that "the trial had met its primary endpoint" at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, US.

What Did The Phase 3 Trial Find?

Also read: Normal Ageing or Alzheimer's? Doctors Explain Six Key Differences to Watch For

The global trial involved 1,535 people with Alzheimer's disease across 230 sites in 13 countries.

Researchers assessed participants using the Clinical Dementia Rating–Sum of Boxes (CDR-SB), which measures memory, judgment and the ability to perform everyday activities.

The findings showed:

  • 31% slower decline: Among 604 patients taking AR1001 without other dementia medications, disease progression was 31% slower than in the placebo group.
  • 3.5-month delay: The difference was equivalent to delaying disease progression by approximately 3.5 months over one year.
  • No significant benefit in the overall group: Among all 1,535 participants, the benefit was 7% and was not statistically significant.

The findings suggest that AR1001's effectiveness may depend on whether patients are taking other Alzheimer's medications.

Dr Richard Oakley, Associate Director for Research and Innovation at Alzheimer's Society, described the results as encouraging.

"These topline results are an encouraging sign that we could have a new treatment for early Alzheimer's disease that tackles its causes, not just its symptoms," Dr Richard said, the Daily Mail reported.

"Over the year of the trial, the drug was able to slow down people's decline in memory and thinking by nearly a third," he added.

Why Is AR1001 Being Called 'Viagra For The Brain'?

Read More: India Gets Its First Alzheimer’s Drug: Know All About Eli Lilly’s Lormalzi

AR1001 works differently from existing Alzheimer's treatments, such as lecanemab and donanemab, which target amyloid plaques in the brain.

Its active ingredient, mirodenafil, belongs to the same class of drugs as sildenafil, the compound used in Viagra to treat erectile dysfunction.

Both drugs inhibit an enzyme called phosphodiesterase-5 (PDE5). This helps relax blood vessels and improve blood flow.

Researchers believe AR1001 may have several effects in the brain, including:

  • Improving blood flow.
  • Reducing inflammation.
  • Protecting nerve cells.
  • Supporting cellular processes involved in brain function.

Unlike some existing disease-modifying treatments that require infusions or injections, AR1001 is designed as a once-daily oral medication.

However, the drug is from the same family of medicines as Viagra and is being developed specifically for Alzheimer's disease. People should not take Viagra to try to treat Alzheimer's.

Are there Any Side Effects?

Most side effects reported during the trial were mild to moderate. Common side effects included diarrhoea, falls and dizziness.

Severe adverse events occurred in 10% of the treatment group and 9.8% of the placebo group.

Researchers also reported changes in biomarkers associated with Alzheimer's disease. Levels of the protein p-tau217 decreased in the monotherapy group, while cerebrospinal fluid cGMP levels increased in both treatment groups.

These findings offer clues about the drug's biological activity, although further research is needed to establish its effects.

However, the lack of a statistically significant benefit among people taking other Alzheimer's medications, adding that this required further investigation.

AR1001 is not yet available to the public and must undergo regulatory assessment before it can be prescribed.

Regulatory approval will depend on further evaluation, including whether the FDA considers the monotherapy results sufficient to support the drug's approval.

End of Article

L'Oréal Settles Hair Relaxer Cancer Cases In First US Trial: Can Chemical Hair Straighteners Cause Cancer?

Updated Nov 17, 2026 | 09:27 AM IST

SummaryL'Oréal USA and several of its subsidiaries recently settled lawsuits related to their chemical hair relaxers and cancer risk in a trial held in Chicago,
L'Oréal Settles Hair Relaxer Cancer Cases In First US Trial: Can Chemical Hair Straighteners Cause Cancer?

Credit: AI-generated image

L'Oréal USA and other manufacturers of chemical hair relaxers have reached a settlement with four women who alleged that years of using hair straightening products contributed to their gynaecological cancers.

The settlement was made during the first US trial involving these claims, bringing newfound attention to research examining the health risks of chemical hair treatments.

What Do We Know About The L'Oréal's US Lawsuit?

According to Reuters, the four women, MaryAnne Lindsey, Surenthia Jenkins, Miranda Lofton and Sandra Simpson, settled their lawsuits for an undisclosed amount. The trial was being held in Chicago.

The women had sued L'Oréal's US subsidiary and several other manufacturers in 2023 and 2024, alleging that prolonged exposure to chemical hair straighteners caused their cancers.

The settlement comes as litigation involving these products continues to surface. More than 12,700 related cases have been consolidated before a federal judge in Chicago.

The products, sold under brand names including Dark and Lovely and Optimum, have been widely marketed to Black women.

Also read: What Is Viral Heightmaxxing? US Doctors Warn Teen Boys Against Taking Cancer Drug To Grow Taller

L'Oréal's Statement

L'Oréal has maintained that its products are safe. A company spokesperson said, "L’Oréal USA strictly follows all regulations in every market in which it operates and its products are always subject to a rigorous scientific evaluation of their safety."

The company has also argued that existing research does not establish that its products caused the conditions alleged in the lawsuits.

What Does Research Say About Hair Relaxers And Cancer?

Scientific interest in the health effects of chemical hair straighteners increased after a 2022 study by researchers at the US National Institutes of Health (NIH).

Published in the Journal of the National Cancer Institute, the study examined data from 33,497 women aged 35-74 participating in the Sister Study.

Over an average follow-up of nearly 11 years, 378 cases of uterine cancer were identified.

Researchers found that women who reported using chemical hair straightening products more than four times in the preceding year had more than twice the risk of developing uterine cancer compared to women who had never used them.

The study estimated that 1.64% of women who had never used hair straighteners would develop uterine cancer by age 70, compared to 4.05% among frequent users.

However, researchers did not focus on the specific brands or chemical ingredients used, meaning they could not identify which substances might have contributed to the observed association.

Also read: Can A 'Sponge On A String' Test Help Detect Oesophageal Cancer Before Symptoms?

High Risk Of Breast And Ovarian Cancer

Other studies have also investigated links between chemical hair treatments and reproductive cancers.

A 2021 study published in Carcinogenesis found that frequent use of hair straighteners and relaxers may cause an increased risk of ovarian cancer. Women who used these products more than four times a year had approximately twice the risk compared with non-users.

Research from the Sister Study cohort has also showed an increased risk of breast cancer due to frequent hair straightener use especially among women who used the products regularly.

However, the findings are not the same across all studies. A 2025 systematic review examining evidence among Black women in the US concluded that the epidemiological evidence that is available did not support an increased risk of breast, ovarian or uterine cancers due to hair relaxer use.

Are Chemicals In Hair Straighteners Dangerous For Health?

Chemical hair relaxers and straighteners contain different substances depending on their formulation. Some products may contain endocrine-disrupting chemicals, including phthalates and parabens, which can interfere with hormonal activity.

Other concerning chemicals include formaldehyde and certain preservatives. Some straightening treatments can release formaldehyde, a recognised carcinogen.

Researchers have suggested that exposure to endocrine-disrupting chemicals could affect hormonal tissues.

End of Article